BioCentury
ARTICLE | Company News

Afraxis, Servier deal

May 13, 2013 7:00 AM UTC

The partners will use Afraxis' Enhanced Spine Platform (ESP) technology to discover treatments for CNS disorders. Afraxis' EPS technology evaluates the preclinical safety and efficacy of CNS compounds by quantifying and characterizing the morphology and maturity of synaptic dendritic spine networks. The partners declined to disclose financial terms. ...